Vijay Pande, founding investor of venture capitalist company Andreessen Horowitz’s Bio + Health fund, discusses advances in biopharmaceutical merger and acquisition (M&A) activity, gene editing, and artificial intelligence (AI) applications in life sciences. He suggests AI shows promise in unlocking the complexities of human disease biology, potentially enhancing the success rate of clinical trials and thereby lowering costs and speeding up drug development. Pande also indicates that M&A activity is expected to surge in 2024.
![](https://healsecurity.com/wp-content/uploads/2024/07/group-ibs-threat-intelligence-and-defence-centre-equip-undergraduates-with-sophisticated.jpg)
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some